EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally
13.9.2023 11:00:00 EEST | Business Wire | Press release
Boomi™, the intelligent connectivity and automation leader, today announced that leading UK-based technology distributor EXERTIS is expanding its use of Boomi’s category-leading, unified integration platform to improve partner and customer satisfaction on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808691045/en/
EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally (Graphic: Business Wire)
EXERTIS works with 2,400 technology partners, including Apple, Samsung, Microsoft, and Dell Technologies, and serves more than 50,000 retailers and resellers in 20+ countries. As part of a full spectrum of services, EXERTIS supplies IT hardware and software to electronic retailers and hosts some clients’ ecommerce stores, managing their full, end-to-end customer journeys.
Prior to using Boomi, EXERTIS had grown through acquisition, where each of its operating entities possessed a mix of legacy and modern integration tools. As a result, manual custom coding; ageing, on-premises enterprise service bus (ESB) systems; and outdated electronic data interchange (EDI) tools and services were widespread and disconnected. This led to slow development and deployment of new integrations, high technical debt, and a declining pool of developers with specialised skills that stifled the scalability and flexibility EXERTIS needed.
With an acquisition strategy that benefitted from inter-company trade synergies, EXERTIS needed a future-proof solution. After evaluating various integration and EDI solutions, EXERTIS saw how Boomi could modernise its IT environment and support its growth and acquisition strategy through the platform’s low-code ease of use; speed of development; and multiple capabilities in a unified, multi-tenant, cloud-based solution.
Using its core integration, B2B/EDI management, and API management capabilities, the Boomi platform enables EXERTIS to connect into over 100 internal and third-party systems with 200 more systems in the pipeline, providing EXERTIS with the agility for further innovation.
“EXERTIS has its origins in venture capitalism and private equity, and a core part of our work centred around the integration of acquired entities,” said Tim Griffin, CEO, EXERTIS. “There are lots of solutions on the market, but I would put Boomi at the top, especially when you consider its multi-tenant architecture and cloud basis. Our developers became proficient in as little as three weeks, and we now have a shared development environment that promotes reuse of integrations across our business.”
In light of its early success, EXERTIS is expanding its use of Boomi to digitally transform its global environment for integration and EDI transactions, and improve partner and customer satisfaction on a global scale.
“We’re delighted to expand our engagement and support of EXERTIS as they continue to grow globally,” said Adrian Trickett, Vice President and General Manager, EMEA at Boomi. “By enabling frictionless transactions, EXERTIS has increased the percentage of orders from its partners and customers, and freed time for its people to pursue more value-adding work.”
Learn more about the EXERTIS use case with Boomi here.
Additional Resources
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organisations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808691045/en/
Contact information
Media:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 14:12:00 EEST | Press release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
